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Associations between rheumatic heart disease (RHD) in pregnancy and fetal outcomes are
relatively unknown. This study aimed to review rates and predictors of major adverse fetal
outcomes of RHD in pregnancy.
Methods
Medline (Ovid), Pubmed, EMcare, Scopus, CINAHL, Informit, and WHOICTRP databases
were searched for studies that reported rates of adverse perinatal events in women with
RHD during pregnancy. Outcomes included preterm birth, intra-uterine growth restriction
(IUGR), low-birth weight (LBW), perinatal death and percutaneous balloon mitral valvulo-
plasty intervention. Meta-analysis of fetal events by the New-York Heart Association
(NYHA) heart failure classification, and the Mitral-valve Area (MVA) severity score was per-
formed with unadjusted random effects models and heterogeneity of risk ratios (RR) was
assessed with the I2 statistic. Quality of evidence was evaluated using the GRADE
approach. The study was registered in PROSPERO (CRD42020161529).
Findings
The search identified 5949 non-duplicate records of which 136 full-text articles were
assessed for eligibility and 22 studies included, 11 studies were eligible for meta-analyses.
In 3928 pregnancies, high rates of preterm birth (9.35%-42.97%), LBW (12.98%-39.70%),
IUGR (6.76%-22.40%) and perinatal death (0.00%-9.41%) were reported. NYHA III/IV pre-
pregnancy was associated with higher rates of preterm birth (5 studies, RR 2.86, 95%CI
1.54–5.33), and perinatal death (6 studies, RR 3.23, 1.92–5.44). Moderate /severe mitral
stenosis (MS) was associated with higher rates of preterm birth (3 studies, RR 2.05, 95%CI
1.02–4.11) and IUGR (3 studies, RR 2.46, 95%CI 1.02–5.95).
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Interpretation
RHD during pregnancy is associated with adverse fetal outcomes. Maternal NYHA III/IV
and moderate/severe MS in particular may predict poor prognosis.
Introduction
The global prevalence of rheumatic heart disease (RHD) is 1%, and is twice as common in
women than men, particularly in women of childbearing age [1, 2]. This figure is likely under-
estimated in developing countries [2]. RHD accounts for approximately 30% of cardiac disease
in pregnancy in developed countries, and 90% of cardiac disease in non-industrialized regions
[3, 4].
Normal hemodynamic changes of pregnancy impose an additional 30–50% cardiac load.
This is well tolerated by a normal heart but can result in morbidity and mortality in women
with pre-existing RHD [5–7]. Mitral stenosis (MS) is especially sensitive to cardiac insuffi-
ciency in pregnancy [8, 9]. The placental-fetal heart circulation is likely affected [10], and
hemodynamic insufficiency poses a risk to the developing fetus. Complications such as intra-
uterine growth restriction (IUGR) and prematurity may have lasting developmental effects
into childhood and beyond [11].
The New York Heart Association (NYHA) functional classification of heart failure is used
worldwide, with four categories (I-IV) based on limitations during physical activity; Class I–
no limit, to Class IV- symptoms at rest [12]. In addition, MS severity can be graded using echo-
cardiography based on mitral-valve area (MVA) into mild (>1.5cm2), moderate (1.0–1.5cm2)
and severe (<1.0cm2) [13]. Increasing severity of these indicators (NYHA, MVA) is associated
with increased frequency of maternal cardiac complications [9]. In contrast, the association
with adverse fetal and neonatal outcomes is often unreported.
The purpose of this study was to review rates of adverse fetal and neonatal outcomes for
women with RHD in pregnancy and investigate the association between increasing severity of
RHD using the NYHA and MVA scales with fetal outcomes. Additionally, the effects of percu-
taneous balloon mitral valvuloplasty (PBMV) on fetal events is reported.
Methods and analysis
This systematic review and meta-analysis is reported in accordance with the PRISMA guide-
lines [14], and registered with PROSPERO (CRD42020161529) [15].
Search strategy
An electronic search of Medline (Ovid), Pubmed, EMcare, Scopus, CINAHL, Informit, and
WHO ICTRP was performed on 15 July 2020, limited to studies published in English language
between 01 January 1990–15 July, 2020.
The complete search strategy (S1 Fig) used combined controlled vocabulary with free-text
words related to population, intervention/exposure, and outcome (PICO). Studies were eligi-
ble for inclusion if they were conducted at a tertiary centre and reported associations between
RHD in pregnancy and one or more pre-specified fetal outcomes. Studies with non-specific
pregnancy-related cardiac disease, concordant congenital heart disease, isolated pulmonary or
aortic valve involvement were excluded. Randomized controlled trials, intervention studies,
cohort studies, case-control studies were eligible for inclusion. Case reports, case series,
reviews, and duplicates were excluded.
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Titles and abstracts were screened by the primary author (JL) on selection criteria. A second
reviewer (BW) screened a sample until agreement reached >0.8 using Cronbach alpha [16].
For all selected articles, the full text were retrieved and evaluated by primary author and inde-
pendent second reviewer (BW) for eligibility. In case of disagreements, a third reviewer was
consulted (CH), and a decision agreed by consensus. Additional studies were identified from a
manual search of references of included studies.
Type of outcome measures
Studies reporting one or more of the following outcomes were included: preterm birth (live
delivery before 37 weeks gestation), low birth weight (LBW) (<2500 grams), small for gesta-
tional age (SGA) or intra-uterine growth restriction (IUGR) (estimated weight <10% percen-
tile for gestational age), miscarriage (non-viable products of conception <20 weeks gestation)
or perinatal death (including stillbirths (fetal demise after 20 weeks) and neonatal deaths
(within the first 28 days of life)).
Data extraction and risk of bias assessment
Data were extracted into custom data collection forms by two independent reviewers (JL,
BW). Authors were contacted for further information if required. Information extracted
included: authors, setting, location, study design, study period and population characteristics
(maternal age, gravida, parity, gestational age, rheumatic valvar lesions, mitral valve area sever-
ity, baseline NYHA classifications and mode of delivery).
Two authors (JL and BW) independently scored the risk of bias with a modified Quality in
Prognostic Studies (QUIPS) tool [17] (S2 Fig). A risk of bias assessment was based on criteria
for study participation, study attribution, prognostic factor measurement, outcome measure-
ment, study confounding and statistical analysis. Each category was classified as low, medium,
high or unknown risk of bias. Discrepancies were resolved by consensus or by a third reviewer
(LH).
Statistical analysis
Rates of neonatal outcomes were recorded and compared based on maternal baseline NYHA
status and MVA severity at the time of first antenatal visit. The effect of minimal invasive inter-
vention (PBMV) during pregnancy on neonatal outcomes was narratively synthesised. An a-
priori decision was made to perform meta-analysis if sufficient data was available. Weight of
the studies in the meta-analysis was calculated based on the Mantel-Haenszel test using Rev-
man v5.4 [18]. The random effects model was chosen to account for inter- and intra-study var-
iability [19, 20]. Between-study heterogeneity was assessed using the I2 test [21]. Risk ratios
(RR) were reported with 95% confidence intervals (CI). Subgroup analysis was conducted
based on country and non-PBMV/PBMV cohorts and sensitivity analysis was conducted with
exclusion of outliers. Small study bias (including publication bias) was examined using funnel
plots and Egger’s test [22] if 10 or more studies were available, with statistical significance set
at 10%.
Evaluating the presented evidence
The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) [23]
system was used to evaluate the certainty of evidence across studies regarding clinical signifi-
cance of NYHA or MVA on fetal outcomes.
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Results
The initial database search identified 9719 papers. A further 4 papers were obtained from
other sources. After removal of duplicates (n = 3774) and ineligible studies from title and
abstract screening (n = 5813) and full text review (n = 114), 22 studies were included in the
review (all cohort study designs) (Fig 1), and 11 in the meta-analysis (Table 1).
Study characteristics and risk of bias assessment
The studies, published from 1990–2020, comprising 3928 pregnancies with rheumatic heart
disease were conducted across countries including India (7), Israel (2), South Africa (2), Nepal
(2), Egypt (2), Canada (1), Australia (3), Brazil (1), Thailand (1). One study involved over 60
countries using the Registry of Pregnancy and Cardiac disease (ROPAC).
Three studies were assessed as high [24–26], 12 moderate [8, 27–37], and 7 low risk [7, 9,
38–42] of bias (Fig 2). Risk of bias was frequently identified in outcome measurements, which
often lacked definition, citing information bias towards the null value. Other risk of bias (3
studies) [24–26] identified were study participation. One study [24] had high risk of bias in the
prognostic factor measurement (NYHA) with values being recorded post-pregnancy. Most
studies were at unknown risk for confounding bias. Eight studies conducted analysis of fetal
outcomes by prognostic factors using univariate analyses. Only Van Hagen et al. [9] used mul-
tivariate analysis in order to adjust for confounding. As such, results from this review regard-
ing risk index of NYHA and MVA should be interpreted in terms of absolute risk, and meta-
analysis is of unadjusted rates.
Preterm birth was the most commonly reported adverse outcome for women with RHD
during pregnancy (Table 2) [7–9, 24–35, 37, 38, 40–42]. Incidence ranged from 9.35%-42.97%,
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0253581.g001
PLOS ONE Rheumatic heart disease in pregnancy and neonatal outcomes: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0253581 June 29, 2021 4 / 19
Table 1. Characteristics of included studies.
Author (year) Country and
setting









Retrospective 183 Maternal age– 25.66
+/-3.90
Moderate Outcomes were for both RHD and congenital heart
disease.










Retrospective 309 NYHA III/IV –14.2% Moderate Average diagnosis of RHD at 26 weeks GA
Education low– 14% illiterate, 10.6% primary schoolPrevious surgery–
9.38%
Severe MS– 36.67%
Maternal age– 25.6 +/-
3.9




Retrospective 500 Maternal age– 25.27
+/- 3.79
Moderate 35 pregnancies lost to follow up.
NYHA III/IV– 22.6% Unclear definitions of perinatal death.
Previous Surgery–
35.6%
Mane SV, et al.
(1993) [26]
India, Mumbai Retrospective 51 Maternal age–not
reported
High LBW was defined as <2000g.
NYHA III/IV– 46.0% No report on antenatal care, GA, co-morbidities.
Maternal anaemia–
13.7%
Unclear timing of NYHA measurement.
Pandey U (2014)
[31]
India, Varanasi Retrospective 96 Maternal age– 79%
between 21–35 years
old
Moderate Timing of NYHA measurement was not specified.
Unclear definition of preterm birth.





India, Kolkata Retrospective 48 Maternal age– 25 +/-
3.4
Moderate Did not report patients with previous cardiac surgery.
NYHA III/IV– 25.0%




Retrospective 31 Maternal age– 30.97
+/- 5.59
Moderate 35 pregnancies were lost to follow up.








Retrospective 820 Maternal age– 25.3
+/-4.4
Low 26.3% were diagnosed during pregnancy.
Prior cardiac
intervention -22.4%
Main outcomes were to create a predictor score for







Retrospective 77 Maternal age– 21–40 Low Definition for LBW was <2kg.




HIV +ve in 32.6%
(Continued)
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Table 1. (Continued)
Author (year) Country and
setting









Prospective 128 Maternal age– 27.00 Moderate 42% new diagnosis in pregnancy.









Prospective 85 Maternal age– 27.34 Moderate Excluded mitral valve repair/replacement, MVA




Not reported NYHA was measured throughout pregnancy and






Prospective 45 Maternal age– 25 +/- 5 High <90% presented for first time at labour
NYHA III/IV– 33.3% No inclusion or exclusion criteria, and no record on
past surgery, anticoagulation or comorbidities.Severe MS– 8.9%
38% had pulmonary
hypertension
Unclear when NYHA was assessed.
Van Hagen et al.
(2019) [9]




Low Over 60 countries are involved in this registry.
Severe MS– 24.77%
(of 218)
Barbosa PJB et al.
(2000) [24]
Brazil, Salvador Retrospective 45 Maternal age– 28.8 +/-
4.6
High NYHA was collected on follow up post-pregnancy for
6 patients.
NYHA III/IV– 86.6%
Severe MS– 42.2% Did record of past surgery, anticoagulants or RHD
specific lesions.




Retrospective 74 Maternal age–not
stated.
Low Only 74/94 infant data was available (<80%). No





Ongzalima C, et al.
(2019) [39]
Australia (WA) Retrospective 53 Maternal age– 26.9 Low Aboriginal mothers were younger in age, and have a








Prospective 314 Maternal age 27 (22–
32)
Low Aboriginal mothers were younger in age, more likely
to smoke in pregnancy, present late to antenatal care,






Prospective 71 Maternal age– 32
+/-5.9
Moderate Did not state patients who were on anticoagulants/
past surgery.
NYHA III/IV– 25.35% SGA definition was <5% predicted weight
Thanajira-prapra
et al. (2009) [37]
Thailand,
Bangkok
Retrospective 133 Maternal age– 27.9
+/-5.8
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with substantial intra- and inter-country variation; Australia [39, 41, 42], (10.81%-21.01%),
India (12.00% -25.12%) [7, 26, 31, 33, 36], Nepal (15.55%-22.35%) [25, 34], Egypt (9.36%-
26.04%) [32, 40] and South Africa (16.88%-41.97%) [28, 38]. Meta-analysis of preterm birth in
women with baseline NYHA included 5 studies (n = 936 pregnancies) [9, 30, 32, 34, 40] and
showed a clear difference in this outcome between NYHA III/IV and NYHA I/II, with a RR
2.86 (95% CI 1.54–5.33, p<0.001). Heterogeneity was high (I2 = 64%) (Fig 3). An outlier study
from Nepal, Sharma et al [34] reported a RR of 8.67 (3.86–19.45) (Fig 3) in comparison to a
RR<3 in all other studies. A post-hoc sensitivity analysis with removal of this outlier result
gave an RR of 2.38 (95% CI 1.56–3.64, p<0.001), and reduced I2 to 12% (Fig 4).
Preterm birth in women with moderate or severe MS, meta-analysis of 3 studies (n = 329)
[8, 9, 35] had a significant unadjusted RR of 2.05 (95% CI 1.02–4.11, p = 0.04) (Fig 5).
Incidence of IUGR/SGA was 6.25% -25.00% among 13 studies (Table 2) [7–9, 27–39, 31–
33, 35–37, 40]. On meta-analyses of 3 studies (n = 546) [32, 33, 40], NYHA III/IV was not sig-
nificantly associated with IUGR/SGA (RR 1.53, 95% CI 0.84–2.80, p = 0.16) (Fig 6), but mod-
erate/severe MS was significant (3 studies, n = 421, RR 2.46, 95% CI 1.02–5.95, p = 0.05) (Fig
7) [8, 9, 35] Subgroup analyses were not undertaken due to the limited number of studies.
Low-birth weight (LBW) rates varied between countries. High rates were seen in India
(32.78–39.70%) [27, 29], Egypt (37.44%) [32], and Brazil (22.22%) [24], compared to Australia
(14.97%) [42] and South Africa (12.98%) (Table 2) [38]. The ROPAC study9 reported LBW
rates of 17.89% across the multiple countries included in the registry. Meta-analysis of 4 stud-
ies (n = 826) [9, 27, 32, 34] found no significant association of NYHA III/IV with LBW (RR
1.74, 95%CI 0.98–3.10, p = 0.06) and had high heterogeneity (I2 = 85%) (Fig 8). Post-hoc sensi-
tivity analysis excluding the outlier study [34] changed the overall significance (RR 1.40, 95%
CI 1.07–1.83, P = 0.01), and reduced statistical heterogeneity (I2 = 9%) (Fig 9).
Perinatal death was reported in most studies [7–9, 24–42]. Incidence of intrauterine death
(IUD) (or stillbirth) varied (0.00%-9.41%), with the highest rates seen in Nepal (8.89%-9.41%)
Table 1. (Continued)
Author (year) Country and
setting





Rezk M, et al.
(2015) [40]
Egypt, Meoufia Prospective 192 Maternal age– 23–24
+/- 3,2








Retrospective 203 Maternal age– 95%
between 20–30 years
old








Prospective 80 Maternal age– 32 +/- 5 Moderate No clear definition of fetal outcomes.
NYHA III/IV– 0% Univariate analysis was not conducted for other
potential confounders.Severe MS– 11%
Previous operated–
34%
SGA/IUGR- small for gestational age/intra-uterine growth restriction; LBW-low birth weight; NYHA-New York Heart Association; MVA-mitral valve area; MS-mitral
stenosis; RHD-rheumatic heart disease; NA-not applicable; GA-gestational age.
https://doi.org/10.1371/journal.pone.0253581.t001
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[25, 34] and South Africa (6.25%-6.49%) [28–38], as did neonatal death rates (0.63%-3.10%)
(Table 2) [7, 32, 34, 38–40].
Meta-analysis of the association of perinatal death and NYHA III/IV pre-pregnancy in 6 eli-
gible studies (n = 1682) [9, 32–34, 36, 40] gave an unadjusted RR 3.23 (95% CI 1.92–5.44,
p<0.001). Heterogeneity was low (I2 = 0%) (Fig 10). Sharma et al. [28] was a clear outlier with
a neonatal mortality rate of 12.94%. Post-hoc sensitivity analysis after exclusion of this study
gave an RR of 2.96 (1.74–5.02, p<0.001) (Fig 11).
Fig 2. Risk of bias assessment for included studies and risk of bias summary.
https://doi.org/10.1371/journal.pone.0253581.g002
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Bhatla et al. (2003)
[27]
183 25.12% 22.40% 32.78% 1.10% NA 2 congenital malformation (TOF, ASD)–none on
anti-coagulants
NYHA
Suri V, et al.
(2019) [36]
309 NA 25.00% Mean BW–
2.4 +/-0.6
3.14% 1.81% Lower GA at delivery in mild/ moderate vs severe MS
(P<0.005)
NYHA
Sawhney H, et al.
(2002 [33]
500 12.00% 18.20% NA 2% NA 10 maternal deaths– 8 in NYHA III/IV, 2 in MV
replacement.
NYHA
Mane SV, et al.
(1993) [26]
51 17.64% NA 17.64%� NA NA SCU admission– 13.72% (1 MAS, 6 premature) NA
Pandey U (2014)
[31]
96 12.50% 8.33% 3.12% 3.12% NA 0 miscarriage NA
3 deaths due to Intraventricular haemorrhage
Shuchi J (2013)
[29]
48 25.00% 6.25% 35.40% 2.10% NA No difference in BW, neonatal death or preterm in




Brezinov OP, et al.
(2019 [8]
31 16.10% 19.35% NA 0% 0% Total adverse event rate was higher in severe MS
when compared to moderate or mild MS (HR 3.15,
95%CI 1.04–9.52) and (HR 4.06, CI 1.14–11.19),
P<0.05, respectively.
MVA
Baghel J, et al.
(2020) [7]
820 20.6% 8.4% 39.7% 1.7% 2.1% 35 miscarriages (4.26%) NA
16.7% required admission to NICU.
Nqayana et al.
(2008 [38]
77 16.88% NA 12.98% 6.49% 1.30% 1 congenital malformation–gastroschisis (neonatal
death)
NA
Desai DK, et al.
(2000) [28]
128 42.97% 16.41% NA 6.25% NA 38% had pulmonary oedema NA
Miscarriage (4.7%)– 4 miscarriage in severe MS
Sharma P, (2017)
[34]





45 15.55% NA Mean BW–
2.6 +/-0.5
8.80% 15.55% Pulmonary H was in 38% of pregnancies. NA
Emergency caesarean in 31% of deliveries.
Van Hagen et al.
(2019) [9]
390 9.63% 9.63% 17.89% NA 1.00% Miscarriage– 4.13% Both
Multivariable–fetal adverse outcome
- AF–OR 1.63 (0.20–8.90)
- Severe MS–OR 3.62 (1.45–9.05)
- Severe MR–OR 2.59 (0.83–8.09)
Anticoagulation during pregnancy–OR 0.63 (0.15–
2.62)
Barbosa PJB et al.
(2000) [24]
45 22.22% NA 22.22% 2.22% Miscarriage– 2.22% NA
35% of NYHA IV had PBMV during surgery
Sartain JB, et al.
(2012) [41]




et al. (2019) [39]
53 NA NA NA 1.83% 1.83% Antenatal attendance was higher in non-Indigenous
population than Aboriginal mothers. P = 0.0078)
NA
Miscarriage– 1.85%
Sullivan EA, et al.
(2019) [42]
314 21.01% NA 14.97% 2.22% NA Higher NICU admission, LBW in Aboriginal mothers
(vs Maori and other), p<0.05
NA





71 25.35% NA NA 0.00% Higher preterm deliveries in RHD (25–38%)
compared to Congenital disease (13–14%, P = 0.062)
NYHA
(Continued)
PLOS ONE Rheumatic heart disease in pregnancy and neonatal outcomes: A systematic review and meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0253581 June 29, 2021 9 / 19
Intervention with percutaneous balloon mitral valvuloplasty (PBMV) during pregnancy
compared to no intervention was reported in 3 studies [29, 32, 36]. Suri et al. reported lower
birth GA [36], and higher perinatal deaths in those with NYHA III/IV who did not undergo
PBMV vs those who did; (GA 37.15+/-1.06 vs 43.8+/-3.61, p = 0.002), and (0% perinatal death
vs 19.4%, p = 0.08) respectively [36]. Lower preterm births in women who underwent PBMV
during pregnancy was also seen in another study [29] but did not reach statistical significance.
No meta-analysis was conducted for this outcome.
Incidence of miscarriage in pregnancy with RHD was investigated in 5 studies [7, 24, 28,
31, 42] Rates varied between 1.85%39–4.70% [28]. One study found 4 out of the 6 miscarriages
in their cohort were attributed to critical MS<1.0cm2 [28]. No studies had a comparator
group for meta-analysis. Congenital malformations were rarely reported [27, 29, 38].
High Neonatal Intensive Care Unit (NICU) admission rates (13.70–42.25%) were reported
in 3 studies [7, 26, 32]. One study found significantly higher NICU admissions associated with
NYHA III/IV pre-pregnancy in women with RHD vs NYHA I/II (42.50% vs 14.20%, P<0.001)
[40].
RHD was first diagnosed during pregnancy in 66.5% of patients in one study [32]. High
rates were also seen in Australia (14.2%) [42], South Africa (42%) [28] and 24.9% in the
ROPAC study [9]. Limited antenatal care in multiple studies [25, 34, 39, 42] was associated

















et al. (2009) [37]
133 11.28% 6.76% 9.77% 0.01% 1 reported birth asphyxia NA
Rezk M, et al.
(2015) [40]
192 26.04% 19.79% NA 2.60% 3.12% Higher NICU admission in NYHA III/IV (47.5%) vs
NYHA I/II (25.8%), P<0.001
NYHA
Pratibha D, et al.
(2009 [32]
203 9.36% 9.36% 37.44% 4.90% 1.00% 27.09% admitted to NICU NYHA
Silverside C et al.
(2003 [35]
80 21.25% 7.50% NA 2.50% MVA
SGA/IUGR- small for gestational age/intra-uterine growth restriction; LBW-low birth weight; IUD-intrauterine death; NYHA-New York Heart Association; MVA-
mitral valve area; TOF-tetralogy of fallot; ASD-Atrial septal defect; GA-gestational age; SCU-special care nursery; MV-mitral valve; MR-mitral regurgitation; NICU-
neonatal intensive care unit; BW-birth weight, MS-mitral stenosis; RHD = rheumatic heart disease; NA-not applicable; PBMV- percutaneous balloon mitral
valvuloplasty.
https://doi.org/10.1371/journal.pone.0253581.t002
Fig 3. Comparison of New York health assessment I/II and New York health assessment III/IV scores for preterm births in women
with baseline New York health assessment scores.
https://doi.org/10.1371/journal.pone.0253581.g003
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One study [9] conducted adjusted analysis and found severe MS was independently associ-
ated with adverse fetal outcomes (OR 3.62, 95%CI 1.45–9.05), when adjusted for atrial fibrilla-
tion, severe mitral regurgitation, and anticoagulation during pregnancy. Pre-pregnancy
NYHA>1 did not show univariate significance with adverse fetal outcomes (OR 1.10, 95% CI
0.59–2.02, p = 0.10), but was an independent predictor of maternal cardiac events in women
with MS [9].
Funnel plot and Eggers test was not conducted as less than 10 studies were included per
meta-analysis. The GRADE system rated the overall certainty of evidence as low for MVA and
NYHA as markers for preterm, and very low for NYHA as markers of SGA/IUGR, LBW and
perinatal death (Table 3). There was also low certainty for MVA and SGA/IUGR.
Discussion
Evidence from the 22 included studies suggest RHD in pregnancy is associated with high rates
of adverse fetal outcomes (preterm birth, LBW, SGA, IUGR, miscarriage and perinatal death).
Additional outcomes found high rates of NICU admissions [26, 32, 40] low rates of antenatal
care and late diagnosis of RHD in many women.
On meta-analysis, both severe MS and NYHA III/IV were significantly associated with pre-
term birth. Additionally, NYHA III/IV were also associated with higher rates of perinatal
death. A Nepalese study [34] appeared to be an outlier in reporting consistently higher rates of
fetal adverse outcomes in their patient cohort. Post-hoc sensitivity analyses excluding this
study lowered statistical heterogeneity and reduced the RR. This could indicate that this site in
Nepal may have wider health care inequities (low health resources, health access, co-morbidi-
ties) compared to other developing countries (India, Egypt etc.).
The association between rheumatic MS during pregnancy and adverse fetal outcomes is
biologically plausible. Early pregnancy is associated with a 30–40% increase in cardiac preload
[43], decreased systematic vascular resistance and systolic blood pressure. These changes are
Fig 4. Sensitivity analyses: Comparison of New York health assessment I/II and New York health assessment III/IV scores for preterm
births in women with baseline New York health assessment scores.
https://doi.org/10.1371/journal.pone.0253581.g004
Fig 5. Comparison of mild and moderate/severe mitral stenosis for preterm births.
https://doi.org/10.1371/journal.pone.0253581.g005
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poorly tolerated in MS and restricted left ventricular inflow with increasing atrial pulmonary
pressures often precipitates cardiac decompensation and pulmonary edema [10]. Adverse fetal
outcomes are likely due to uteroplacental insufficiency secondary to left heart obstruction [10].
Poor oxygen and nutrient transfer may lead to stunted fetal growth.
Mitral stenosis carries a high risk of chronic fetal hypoxia and early onset (<32 weeks)
IUGR in pregnancy. These fetuses are more likely born preterm, and are high risk of rapid
deterioration, fetal demise in-utero and stillbirth [44]. There are also recognised links of IUGR
with cardio-vascular remodelling, sub-optimal renal and neurological development, and
altered glucose metabolism; collectively known as the fetal origin hypothesis [45]. Such out-
comes are currently unexplored in neonates born to mothers with RHD.
The prognostic value of NYHA classification for neonatal outcomes is likely a reflection of
the severity of the pressure gradient across the mitral valve and underlying pulmonary edema.
As such, it is well established in predicting maternal cardiac events, but less so for adverse fetal
events. This review found NYHA class III/IV had significant associations with prematurity
and perinatal death, but not LBW or IUGR/SGA. Conversely, mitral valve area (MVA) deter-
mined by echocardiogram could more directly indicate cardiac output and uteroplacental per-
fusion as moderate/severe MS was significantly associated with both SGA/IUGR and
prematurity.
RHD remains the predominant form of maternal heart disease in pregnancy in developing
nations [3, 4]. In this study, developing countries [46] (India, Nepal, Egypt, South Africa)
exhibited relatively higher rates of adverse neonatal outcomes compared to developed coun-
tries (Australia, New Zealand). Shortage of health services and delayed access to tertiary cen-
tres may be more evident in these developing nations, with further limited capacity of
hospitals in surgical intervention [29] and neonatal intensive care [34].
Poorer education among women with RHD was reported in one study in Chandigarh,
India [36]; 14% illiterate and 10.6% only receiving a primary school education. Downstream
Fig 6. Comparison of New York health assessment I/II and New York health assessment III/IV for Intra-uterine growth restriction/
small for gestational age outcome.
https://doi.org/10.1371/journal.pone.0253581.g006
Fig 7. Comparison of mild and moderate/severe mitral stenosis severity for intra-uterine growth restriction/small for gestational age
outcome.
https://doi.org/10.1371/journal.pone.0253581.g007
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health behaviours associated with low education status, such as younger maternal age and mul-
tiparity are also predictors for adverse perinatal events [47].
Within-country variations in birth outcomes were observed in western developed nations.
One study found higher rates of preterm and perinatal death in Aboriginal Australians or Tor-
res Strait Islanders, and Maori or Pasifika mothers compared to non-Indigenous counterparts
[42]. Indigenous mothers with RHD were significantly younger, [39, 42] more likely to present
>20 weeks to antenatal clinic, be socioeconomically disadvantaged, and smoke during preg-
nancy compared to non-Indigenous mothers [42]. While the disparity in fetal outcomes is
likely a combination of these bio-psychosocial factors, there is evidence of an independent
association of RHD in pregnancy. For example, in Australia, one study [42] reported an overall
preterm birth rate of 21%; much higher than the overall rate of Australia (9%) and of babies
born to Indigenous mothers (14%) [48] As such, closing the gap between health inequities
among disadvantaged populations is a priority in the improvement of global neonatal health,
and eradication of RHD among women of child-bearing age.
Antenatal care remains a critical component of neonatal outcomes in RHD patients [49].
Sub-optimal antenatal visits were common among studies with relatively higher adverse fetal
events. In one study [25] over 90% of women presented for first time in labour and reported a
high IUD rate (6.25%). In Durban (South Africa) [38] 62% had first cardiac evaluation in 3rd
trimester and had 42.97% prematurity deliveries. Greater emphasis on pregnancy planning,
particularly after an index pregnancy would be beneficial.
Pregnancy planning and early initial antenatal consultation is also important for women
with a surgical valve replacement and on lifelong anticoagulants such as warfarin. Delayed ini-
tial antenatal visits and low uptake of contraceptives [50] were reported among this sub-group
of women in several studies [34, 38]. This is concerning as warfarin is teratogenic and has
strong associations with fetal malformation, abortion and stillbirth. Early optimisation with
heparin or low-molecular weight heparin should be a priority in these patients [51].
Fig 8. Comparison of New York health assessment I/II and New York health assessment III/IV for low birth weight outcome.
https://doi.org/10.1371/journal.pone.0253581.g008
Fig 9. Sensitivity analyses—comparison of New York health assessment I/II and New York health assessment III/IV for low birth
weight outcome.
https://doi.org/10.1371/journal.pone.0253581.g009
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PBMV remains the treatment of choice for isolated non-calcified MS and is safe to perform
during pregnancy, with few adverse maternal or fetal events [52–54]. This systematic review
suggests PBMV in women with severe symptoms (NYHA III/IV) is associated with reduced
rates of preterm births; however further comparative studies are required. No long-term effects
on child development have been reported to date [52, 55, 56].
Mitral valve surgery involving cardiac bypass was not assessed in this review as such inter-
ventions are avoided where possible during pregnancy due to the significantly high associated
fetal mortality (ranging from 5–33%) [54, 57].
Limitations
Neonatal outcomes are influenced by a complex interplay of known and unknown factors.
RHD is associated with socio-economically disadvantage, and many important potentially
confounding variables such as smoking, poor antenatal care, chronic disease [58] and extent of
RHD-related antenatal services in hospitals of different countries, which were not measured in
the included studies. Insufficient reporting on outcomes of women on warfarin during preg-
nancy also limited analysis of a clinically important sub-group.
Only studies based at tertiary hospitals were included, and it is likely that lower-resourced
and rural areas experience even poorer pregnancy outcomes that are underreported.
There is some methodological limitation in this research. First, most studies in this review
had moderate risk of bias in multiple domains. In particular, outcome definitions were not
clearly explained, and influence of confounders was also uncertain. Second, there is a possibil-
ity of publication bias among studies with small samples, particularly in outcomes around peri-
natal death. Overestimation of the true effect size may have resulted from smaller studies with
Fig 10. Comparison of New York health assessment I/II and New York health assessment III/IV for perinatal death outcome.
https://doi.org/10.1371/journal.pone.0253581.g010
Fig 11. Sensitivity analyses–comparison of New York health assessment I/II and New York health assessment III/IV for perinatal
death outcome.
https://doi.org/10.1371/journal.pone.0253581.g011
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non-significant findings not being published. Third, there was clinical and statistical heteroge-
neity between studies. The overall certainty of the evidence generated from meta-analysis was
low or very low (Table 3), although the GRADE system allows a maximum of low-quality evi-
dence for meta-analysis of cohort studies [59].
These findings are important from a national, international, public health policy perspec-
tive, highlighting increased perinatal morbidity and mortality in infants born to women with
RHD. As our results indicate that moderate or severe MS, symptomatic NYHA, have worse
outcomes, we recommend early specialist involvement in these cases. While no definitive man-
agement for IUGR exists besides delivery, neonatal USS Doppler could be useful for early iden-
tification. PBMV in pregnancy is an effective, low risk procedure for symptom relief in MS
during pregnancy but requires further research. Finally, our findings add support to large scale
echocardiographic screening of RHD in pregnancy in high-risk populations.
Large, well-designed prospective studies of pregnancy in women with RHD are required.
Associations with NYHA and MVA severity on neonatal outcomes need to be calculated based
on adjusted rates. One study [9] in this systematic review demonstrated robust methodology
that could be modelled in future studies.
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Table 3. Assessment of quality of evidence of NYHA and MVA as risk indexes for adverse fetal events in RHD during pregnancy by the Grades of Recommendation
Assessment, Development and Evaluation (GRADE) approach.
No. studies Design Risk of bias Inconsistency Indirectness Imprecision Certainty (overall score)�
Preterm
NYHA 5 Observational Low LowA Low Low Low��
MVA 3 Observational Low Low Low Low Low��
SGA/IUGR
NYHA 3 Observational Low Low Low Very LowB Very Low�
MVA 3 Observational Low Low Low Low Low��
LBW
NYHA 4 Observational Low Low Low Very LowC Very Low�
MVA NA
Perinatal Death
NYHA 6 Observational Low Low Very lowD Low Very Low�
MVA NA
� Meta-analysis of observational studies has an initial confidence estimate of ‘Low confidence’[43]. No outcome was rated up in confidence as analysis did not yield a
sufficiently large effect size.
A- The evidence was kept as low after sensitivity analyses (95%CI 1.56–3.64, I2 = 12%) removing an outlier study.
B- The evidence was downgraded to very low due to the significant difference in clinical implications of the lower and upper limits of the overall CI (0.84–2.80).
C- The evidence was downgraded as the CI is wide and crosses no significant effect CI (0.98–3.10).
D- The evidence was downgraded to very low as perinatal death did not specify between women with PBMV vs non-PBMV, or women on anticoagulant. Both factors
have shown to significantly influence maternal mortality (and fetal death) [44, 45].
https://doi.org/10.1371/journal.pone.0253581.t003
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